Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease

Código QR

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease

Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Medical Affairs, Sun Pharmaceutical Industries, Princeton, NJ, USA; 3Medical Services, Indegene, Inc, Bangalore, IndiaCorrespondence: Abayomi OgundeleM...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	physician satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8db4b64bb83a47058d929b6e1e983ae5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
por: Epitropoulos AT, et al.
Publicado: (2020)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah RT, et al.
Publicado: (2019)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett IV, et al.
Publicado: (2018)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
por: McDonald MB, et al.
Publicado: (2018)

Patient-reported severity of dry eye and quality of life in diabetes
por: Yazdani-Ibn-Taz MK, et al.
Publicado: (2019)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian J, et al.
Publicado: (2020)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2017)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016)

Frequency and risk factors associated with dry eye in patients attending a tertiary care ophthalmology center in Mexico City
por: Martinez JD, et al.
Publicado: (2016)

Short-Term Therapeutic Effects of Topical Corticosteroids on Refractory Dry Eye Disease: Clinical Usefulness of Matrix Metalloproteinase 9 Testing as a Response Prediction Marker
por: Ryu KJ, et al.
Publicado: (2021)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
por: Sambursky R
Publicado: (2016)

Cyclosporine A micellar delivery system for dry eyes
por: Kang H, et al.
Publicado: (2016)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber J, et al.
Publicado: (2018)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

Ocular Surface Changes in Patients with Thyroid Eye Disease: An Observational Clinical Study
por: Allam IY, et al.
Publicado: (2021)

Treatment of Dry Eye With Intracanalicular Injection of Hydroxybutyl Chitosan: A Prospective Randomized Clinical Trial
por: Tong Lin, et al.
Publicado: (2021)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
por: Yeu E, et al.
Publicado: (2020)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols KK, et al.
Publicado: (2018)

A Retrospective Data Review Confirms That Topical Preservative-Free Hydrocortisone Improves Inflammation in Dry Eye Disease
por: Kuzmanović Elabjer B, et al.
Publicado: (2020)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
por: Silverstein S, et al.
Publicado: (2020)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian JA, et al.
Publicado: (2021)

Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
por: Fogagnolo P, et al.
Publicado: (2020)

Patient satisfaction and self-reported dry eye symptoms in hyperopic patients treated with femtosecond laser in situ keratomileusis
por: Mäkinen P, et al.
Publicado: (2019)

Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
por: Molina-Solana P, et al.
Publicado: (2020)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez AL
Publicado: (2018)

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
por: Taylor M, et al.
Publicado: (2019)

Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
por: Nasser L, et al.
Publicado: (2018)